Global clinical trial underway in 11 countries, including U.S., European, and Eastern European sites to evaluate safety, efficacy and tolerability of orally administered, gut-restricted LANCL2 agonist BT-11, in patients with mild to moderate ulcerative colitis
August 20, 2019
· 7 min read